It has been demonstrated that EGFR-TKIs competitively bound with EGFR and blocked several downstream signaling pathways including PI3K/Akt and MARK/Erk, resulted in inhibition of tumor cell proliferation, tumor vascularization and metastasis [21], [22]. Here, MARK1 is linked to neoplasm.